Physician profile

Maninder K Abraham

Internal Medicine · Livingston, NJ

NPI 1194731414

$856.27

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$112.74

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $297.72 2019-2022
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $124.67 2022
Astrazeneca Pharmaceuticals Lp $124.51 2019
Gilead Sciences, INC. $88.64 2022
Shionogi INC $78.12 2023 Fetroja
Pfizer INC. $48.95 2019-2020
Abbvie INC. $34.62 2023 Dalvance
Allergan, INC. $29.64 2019
Amgen INC. $14.93 2020
Novartis Pharmaceuticals Corporation $14.47 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Maninder K Abraham

$856.27

in general payments reported 2019-2025

Years
2019-2023
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/190321/maninder-k-abraham

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.